Evommune (EVMN) EBIT Margin (2025)
Evommune (EVMN) reported EBIT Margin of 133.28% for Q3 2025, up 73.4% quarter-over-quarter from 501.07% in Q1 2025.
Evommune (EVMN) EBIT Margin (2025) Analysis & Trends
Evommune (EVMN) has 1 years of EBIT Margin data on file, last reported at 133.28% in Q3 2025.
- EBIT Margin for Q3 2025 came in at 133.28%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 631.0% (changed N/A YoY), and the FY2025 annual result was 623.62%, up 37656.0% from the prior year.
- EBIT Margin advanced to 133.28% in Q3 2025 per EVMN's latest filing, from 501.07% in the prior quarter.
- Over five years, EBIT Margin peaked at 133.28% in Q3 2025 and troughed at 501.07% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Evommune | 695.29 Mn | 483.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -133.28% |
| Mar 31, 2025 | -501.07% |